Packaging in pharmaceutical pumps is more than simply putting a pump inside a bottle. It is a container-closure and drug-delivery system designed to protect the formulation while ensuring that the correct amount of medicine is delivered consistently.

This is especially important for nasal sprays, topical medicines, ophthalmic products and other pump-based formulations where the package directly influences product stability, sterility and dosing performance. FDA guidance defines a container-closure system as the packaging components that together contain and protect the drug product.

According to Towards Healthcare Research and Consulting, the global pharmaceutical pump market size was estimated at USD 12.84 billion in 2025 and is predicted to increase from USD 13.85 billion in 2026 to approximately USD 27.46 billion by 2035, expanding at a CAGR of 7.9% from 2026 to 2035.

Role of Packaging in Pharmaceutical Pumps

The packaging has to protect the formulation from microbial contamination, moisture, oxygen, light and physical damage, depending on the drug's characteristics.

For pump systems, packaging also controls the flow path and dose delivery. EMA specifically notes that valve and pump systems need clear consideration of product flow, air intake and microbial protection of incoming air.

A well-designed package therefore combines the container, pump mechanism, actuator, dip tube, seals, closures and other components into one controlled delivery system.

How Packaging Is Done in Pharmaceutical Pumps

The process normally starts with selecting compatible materials such as pharmaceutical-grade plastics, glass, elastomers or suitable metal components.

The formulation is filled into the primary container, followed by pump insertion, crimping or closure, depending on the design. Components are then inspected and tested for leakage, dose consistency, functionality and container-closure integrity.

For sterile or sensitive products, additional controls may include sterilization or depyrogenation of components, environmental controls and integrity testing. FDA guidance specifically highlights protection, compatibility, safety and performance testing for pharmaceutical packaging components.

Investment Opportunities

Investment is already reaching significant levels across pharmaceutical packaging and drug-delivery infrastructure.

• Sharp Services invested $20 million in 2025 in autoinjector and pen assembly, labeling and packaging lines in the U.S.
• Sharp announced more than €20 million in 2026 for European injectable packaging, including autoinjectors, pens, prefilled syringes and vials.
• Amcor announced a multi-million-dollar investment in its Sira, Karnataka healthcare packaging facility in 2026, including automated vision systems for ophthalmic containers and injectable vials.
• In India, PAG acquired a majority stake in Pravesha Industries at a $200 million valuation in 2025, highlighting investor interest in pharmaceutical packaging infrastructure.

Pros

• Improves dose accuracy and delivery consistency.
• Protects medicines from contamination and environmental exposure.
• Supports patient-friendly and convenient drug administration.
• Enables controlled dispensing and reduced product wastage.
• Creates opportunities for automation and high-precision manufacturing.

Cons

• High initial investment in specialized machinery and testing.
• Complex validation is required for drug-contact components.
• Material incompatibility can affect formulation stability.
• Pump failures can directly affect dose delivery.
• Regulatory changes can increase testing and documentation requirements.